

```
a513
index_of_first_seq_res: 12 position 13 len=8
K|E|G|V|V|A|A|E|K <----> RQIVSAR antiparallel
(CamSol(range)=1.687232)
| : : : : : --+--+ (ME=1.270378)
|| | |I|V|S|A|R| | | count= 1 promiscuity= 0
V|R|Q| | | | | | | count= 2 promiscuity= 35
|| | |Q|I|V| | | | | count= 1 promiscuity=165
|| | | | | | |R|I|V| | count= 1 promiscuity=195
VV|R| | | | | | | count= 1 promiscuity=391

a528
index_of_first_seq_res: 27 position 28 len=8
A|E|A|A|G|K|T|K|E|G <----> REANYNEI antiparallel
(CamSol(range)=2.092692)
| : : : : : +-+--+ (ME=1.420449)
|| | |N|Y|N|E|I| | | count= 1 promiscuity= 0
M|R|E| | | | | | | count= 1 promiscuity= 9
|| |E|A|N| | | | | | count= 3 promiscuity= 39

a535
Targeting REGION P1 of Sheena Radford paper:
index_of_first_seq_res: 34 position 35 len=8
K|E|G|V|L|Y|V|G|S|K <----> RITAVGHV antiparallel
(CamSol(range)=0.869799)
| : : : : : +-+--+ (ME=1.114625)
|| | |T|A|V|G|H|V| | | count= 1 promiscuity= 0
Y|R|I| | | | | | | count= 1 promiscuity= 85
||R|I|T| | | | | | | count= 1 promiscuity=240

a546
index_of_first_seq_res: 45 position 46 len=8
K|E|G|V|V|H|G|V|A|T <----> RILSGVYL antiparallel
(CamSol(range)=0.657795)
| : : : : : +-+--+ (ME=1.163247)
|| | |S|G|V|Y|L|V| | | count= 1 promiscuity= 0
Y|R|I| | | | | | | count= 1 promiscuity= 85
|| |I|L|S| | | | | | | count= 1 promiscuity=275
|| |I|F|S| | | | | | | count= 1 promiscuity=123
|| |N|I|L| | | | | | | count= 1 promiscuity=141
|| |I|M|S| | | | | | | count= 1 promiscuity= 35
|| |K|I|P| | | | | | | count= 1 promiscuity= 46
|| |I|P|S| | | | | | | count= 1 promiscuity= 27
L|R|A| | | | | | | | count= 1 promiscuity=207
|| |A|V|S| | | | | | | count= 1 promiscuity=230
|| |K|L|V| | | | | | | count= 1 promiscuity=298
|| |L|V|S| | | | | | | count= 1 promiscuity=245

a549
index_of_first_seq_res: 48 position 49 len=8
E|V|V|H|G|V|A|T|V|A|E <----> SGVYLVE antiparallel
(CamSol(range)=0.615874)
| : : : : : --+--+ (ME=0.933835)
||S|G|V|Y|L|V|G| | | count= 1 promiscuity= 0
+ -|| | | | | |V|G|E| | | count= 3 promiscuity= 79
N|Q|S| | | | | | | | count= 1 promiscuity= 15


a561
index_of_first_seq_res: 61 position 62 len=8
E|Q|V|T|N|V|G|G|A|V <----> QYSVLIDADV antiparallel
(CamSol(range)=0.809011)
| : : : : : =---+--+ (ME=0.918387)
Q|Y|S|V|L|I| | | | | count= 1 promiscuity= 0
|| | | | |I|D|A| | | count= 2 promiscuity= 77
|| | | | | |A|D|V| | | count= 1 promiscuity= 78

a568
G|G|A|V|V|T|G|V|T|A <----> YLQSVAEQL antiparallel
(CamSol(range)=1.246822)
| : : : : : ++---+--+ (ME=1.059429)
|| | |S|V|A|E|Q| | | count= 1 promiscuity= 0
S|Y|L| | | | | | | | count= 1 promiscuity=170
||Y|L|Q| | | | | | | | count= 1 promiscuity=141
|| |L|Q|S| | | | | | | | count= 2 promiscuity= 49
|| | | | |Q|L|S| | | | | count= 1 promiscuity=110
|| | | | | | |S|I|F| | | | count= 1 promiscuity=104
|| | | | | |L|S|I| | | | | count= 1 promiscuity=280
|| | | | |Q|L|T| | | | | count=12 promiscuity=216
|| | | | |L|T|V| | | | | count= 2 promiscuity=1084


a570
index_of_first_seq_res: 70 position 71 len=8
V|V|T|G|V|T|A|V|A|Q <----> YGHGIGHEK antiparallel
(CamSol(range)=1.944163)
| : : : : : +++---- (ME=1.012048)
Y| | |I|G|H|E|K| | | | | count= 2 promiscuity= 0
Y|G|H| | | | | | | | | count= 1 promiscuity= 13
||G|H|G| | | | | | | | count= 1 promiscuity= 11
|| |G|I|G| | | | | | | | count= 1 promiscuity= 90

a574
index_of_first_seq_res: 73 position 74 len=8
G|V|T|A|V|A|Q|K|T|VE <----> LEIKAKPTV antiparallel
(CamSol(range)=1.818182)
| : : : : : +-+--+ (ME=1.175002)
|| |E|I|K|A|K| | | | | count= 1 promiscuity= 0
E|L|E| | | | | | | | | count= 1 promiscuity=208
|| | | | |K|F|T| | | | | count= 1 promiscuity=193
|| | | | | |F|T|A| | | | | count= 1 promiscuity=216
||L|E|I| | | | | | | | | count= 1 promiscuity=347
|| | | | |K|F|T|V| | | | | count= 1 promiscuity= 18
|| | | | | |T|VK| | | | | count= 4 promiscuity=417(CamSol(range)=0.836080)
```


**Figure S1. Antibody designs generated with the cascade method.** Details of the sequence fragments used to build the complementary peptides are shown.




**Figure S2: SDS-PAGE analysis of purified DesAbs.** Labels at the well entry denote the DesAb name. MW, molecular weight; kDa, kiloDalton.




**Figure S3: Thermostability and structure of designed antibodies against  $\alpha$ -synuclein.** Circular dichroism (CD) spectra using a constant temperature of 22 °C (upper panels), and thermal denaturation at temperatures ranging from 20 °C to 90 °C was recorded at a constant wavelength of 207 nm (lower panels). Error bars represent +/- s.d. of three technical repeats.  $[\theta]$  mean residue ellipticity.




**Figure S4: Thermal stability of the DesAbs.** aS61 was buffer exchanged to MES buffer (10 mM 2-(N-morpholino)ethanesulfonic acid, 1 mM Ethylenediaminetetraacetic acid (EDTA), pH 5.5) and incubated for 5 days at 37 °C under quiescent conditions as used in the  $\alpha$ -synuclein aggregation assay. The antibody conformation was conserved as shown in: CD spectra **(a)**, thermal denaturation curve measured using CD **(b)**, and thermal denaturation measured using a Tycho NT.6 system **(d)**. DesAbs measurements taken at time T0 and time T5 correspond to the beginning and end of the incubation, respectively. Error bars represent  $\pm$  s.d. of three technical repeats.  $[\theta]$ , mean residue ellipticity. **(c)** SDS-PAGE analysis of two DesAbs which have been incubated in MES buffer at 37 °C for five days. Larger molecular weight species and a band at the entry of the wells (dashed lines) are not present indicating that DesAbs are not aggregating at these conditions. MW, molecular weight; kDa, kiloDalton; RA, reducing agent.



**Figure S5: DesAb lacking an engrafted paratope (DesAb-None) and DesAb against A $\beta$  do not inhibit the aggregation of  $\alpha$ -synuclein.** Normalized ThT traces of seeded aggregation assays (0.06% preformed seeds in 40  $\mu$ M monomeric  $\alpha$ -synuclein in the presence of different DesAbs at variable concentrations. A logistic equation is used to fit the data (pink dashed lines). Reactive oligomer flux ( $\phi$ ) is depicted as characteristic bell shape and is plotted against time (see Eq. 7). Shaded regions correspond to  $\pm$  s.d. of three technical replicates.




**Figure S6: The ThT fluorescence is not affected by the presence of DesAb aS13.** ThT traces in the presence of 320 nM DesAb aS13 (blue) or seeded  $\alpha$ -synuclein (0.06% preformed seeds in 40  $\mu$ M monomeric  $\alpha$ -synuclein; brown). Shaded areas correspond to  $\pm$  s.d. of three technical replicates.




**Figure S7: DesAb aS46 affects the aggregation of  $\alpha$ -synuclein at neutral pH in the presence of lipid vesicles.** Normalized ThT traces in the presence of lipid vesicles (100  $\mu$ M DMPS in 20  $\mu$ M monomeric  $\alpha$ -synuclein) and of DesAb aS46 at varying concentrations. Shaded areas correspond to  $\pm$  s.d. of two technical replicates.

**a**




**b**




**Figure S8: TEM images of  $\alpha$ -synuclein fibrils.** TEM images from an  $\alpha$ -synuclein aggregation (low seed, 0.06% preformed  $\alpha$ -synuclein seeds, 40  $\mu$ M  $\alpha$ -synuclein monomer, MES buffer, pH 5.5) (a) without the presence of DesAb (Control), and (b) in the presence of 1:500 DesAb aS46 relative to monomer. Scale bar, 500 nm.







**Figure S9: DesAbs do not detect  $\alpha$ -synuclein fibrils in a SiMPull assay.** Detected spots per field of view for different conditions varying by the detection antibody used. Error bars denote  $\pm$  s.d. ( $n > 9$ ). Data were analyzed using a one-way analysis of variance (ANOVA). \*\*\*\*  $p < 0.0001$ ; ns, not significant. Det. AB, detection antibody; SC, Santa Cruz antibody; F, fibrils; -, PBS control.




**Figure S10: DesAb aS46 selectively detects  $\alpha$ -synuclein oligomers in PD serum.** The number of detected spots per field of view is shown for a SiMPull experiment in which the SC antibody was used as a capture antibody, PD serum, recombinant monomeric  $\alpha$ -synuclein (500 nM), or PBS used as a sample and DesAb aS46 as a detection antibody. Error bars denote  $\pm$  s.d. ( $n > 4$ ). Data were analyzed using a one-way analysis of variance (ANOVA). \*\*\*\*  $p < 0.0001$ ; ns, not significant.




**Figure S11. SiMPull experiments to estimate the binding affinity and the capturing ability of aS46 for  $\alpha$ -synuclein aggregates in PD serum. (a)** By varying the concentration of fluorophore-labelled aS46 and fitting the determined spots per field of view, a  $K_d$  of 41 nM ( $R^2=0.96$ ) to  $\alpha$ -synuclein aggregates detected in PD serum was estimated. **(b)** Biotinylated aS46 was used as capture antibody and fluorescently labelled aS46 as detection antibody. Data were analyzed using an unpaired t-test. \*\*\*\*  $p < 0.0001$ .



**Figure S12. DesAb aS46 detects  $\alpha$ -synuclein aggregates in the CSF of PD patients.** The number of detected spots per field of view is shown. Error bars denote  $\pm$  s.d. ( $n \geq 50$ ). Data were analyzed using an unpaired t-test. \*\*\*\*  $p < 0.0001$ .



**Figure S13. At low pH, aS28, aS46 and aS68 bind monomeric  $\alpha$ -synuclein with low  $\mu\text{M}$  affinity.** MST measurements showing the characteristic binding curve for three DesAbs at mild pH as used in kinetic aggregation assay. Error bars denote  $\pm$  s.d. of three repeats.



**Figure S14. Experimental setup and sensor loading in BLI experiment. (a)** Biosensor is loaded with  $\alpha$ -synuclein fibrils. **(b)** BLI curves recorded for the loading of biosensors